Regulatory Authorities Worldwide are Scrutinizing GDPs During Inspections
This article was originally published in PharmAsia News
Regulators worldwide are increasingly scrutinizing pharmaceutical manufacturers’ good distribution practices during GMP inspections as GDP regulations continue to proliferate, says an industry representative who discusses how to comply with different regulations.
You may also be interested in...
The European Commission needs to fine tune its good distribution practices (GDP) guideline, the pharmaceutical industry said in comments on a proposed draft revision. Key issues include segregating EU and non-EU product, transportation vs. storage conditions, applicability to investigational products and time limits for transportation hubs.
US FDA officials tell industry that implementing a quality metrics program is an agency priority and that a rejiggered program will incorporate various elements of other quality metrics initiatives being piloted by the agency, industry and academia.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.